Vepdegestrant, an oral PROTAC, nearly doubles progression-free survival in ESR1-mutated, ER-positive advanced breast cancer, ...

"The said acts of disregarding regulators’ directions reflected poorly on the conduct of Noticees 1 (Singh) and 2 (Mishra), as Board members of PFS," the order said. Queries sent to PTC India ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; ...

PTC India Financial Services' director Rajib Kumar Mishra, who is also the CMD of PTC India, and PFS' former MD and CEO Pawan Singh have been fined Rs 10 lakh and Rs 25 lakh respectively by the ...

Adding dostarlimab to platinum-based chemotherapy and niraparib improved PFS in patients with advanced ovarian cancer.

PTC India Ltd (BOM:532524) reports robust trading volume growth and successful divestment, despite challenges in operational income and consultancy setbacks.